TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has launched the new Shake & Puff CBN THC Nighttime Inhaler in Canada. This innovative product expands MediPharm's leading CBN oil product portfolio and builds on the success of the Company's THC Inhaler introduced earlier this year. Metered dose inhaler format e ...

Core Viewpoint - MediPharm Labs Corp. has received a recommendation from Glass Lewis to support its nominees for the Board of Directors in the upcoming shareholder meeting on June 16, 2025 [1][2] Group 1: Shareholder Voting - Glass Lewis is the second independent proxy advisory firm to recommend voting for the Company's nominees, following a similar recommendation from ISS [2] - MediPharm urges shareholders to vote using the GREEN proxy to support all nominees and resolutions, with votes due by 3:00 p.m. Eastern time on June 13, 2025 [3] - Shareholders are encouraged to contact their broker for their control number to ensure their vote is counted [4] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and products [5] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP License for cannabinoid extraction [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the application (CV-25-00743454-00CL) (the “Application”) issued by Apollo Technology Capital Corporation (“Apollo”) and Nobul Technologies Inc. (together with Apollo, the “Applicants”) against t ...

Core Viewpoint - Institutional Shareholder Services (ISS) recommends that MediPharm shareholders vote for the company's nominees for the Board of Directors, stating that the dissident, Apollo, has not presented a compelling case for change [2][6]. Group 1: ISS Report Findings - The ISS Report concludes that Apollo's claims lack sufficient evidence, highlighting that since Q2 2022, quarterly revenues have more than doubled, adjusted EBITDA has improved from a $6.3 million loss to a $0.1 million gain, and gross margins have expanded by 50.9 percentage points [4][5]. - The report indicates that MediPharm has shown multiple years of improving financial results, particularly under CEO David Pidduck's leadership, and has a logical strategy focusing on higher margin international markets [4][5]. - The ISS Report states that the company has generally outperformed its peers and experienced a clear operational turnaround, contradicting the dissident's claims of peril [4][5]. Group 2: Recommendations for Shareholders - ISS recommends that shareholders vote for the resolution to fix the number of directors at seven, approve MNP LLP as auditors, and authorize the Board to fix their remuneration [6]. - Shareholders are advised to vote against the resolution to approve all unallocated awards under the Company's equity incentive plan [6]. - MediPharm urges shareholders to use the GREEN proxy or voting instruction form to support all of the Company's nominees and resolutions [7][8]. Group 3: Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and has a GMP-certified facility [9]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale domestic GMP License for cannabinoid extraction [10]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada and internationally [11].

TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited (“Blackpoint”), MediPharm’s exclusive sales and distribution partner in those territories. ...

Core Viewpoint - MediPharm Labs Corp. has successfully removed all conditions precedent related to the sale of its Hope Facility to Rubicon Organics Inc. for $4.5 million, which is expected to close in June 2025, enhancing the company's cash position and maintaining its virtually debt-free status [1][2][3]. Financial Impact - The $4.5 million proceeds from the sale will support MediPharm's strategy to deliver long-term value for shareholders and partners, focusing on international growth and acquisition opportunities [3]. - Since the implementation of its cost-reduction strategy in Q2 2022, MediPharm has reduced operating and overhead costs by approximately $42 million annually [4]. Asset Management - The Hope Facility was acquired during the VIVO Cannabis Inc. acquisition in 2023, and all commercial activities at this facility ceased in 2024, consolidating operations at other facilities to reduce costs [3]. - The total value of asset sales since 2022, including the Hope Facility, amounts to approximately $14 million, contributing to cost reduction and strengthening the balance sheet [3]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and products, operating under Good Manufacturing Practices [5]. - The company holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [6]. - The acquisition of VIVO Cannabis Inc. in 2023 expanded MediPharm's reach to medical patients in Canada, Australia, and Germany [7].

Core Viewpoint - MediPharm Labs Corp. is addressing concerns regarding Regan McGee, a dissident shareholder and CEO of Apollo Technology Capital Corporation, who is seeking to elect himself and five other directors to the MediPharm board at the upcoming shareholder meeting [1][2]. Group 1: Allegations Against Regan McGee - Allegations have been made against Mr. McGee regarding his business conduct, including claims of misusing company resources and setting his own compensation through a conflicted process [3][6]. - Former colleagues of Mr. McGee have accused him of misrepresenting the nature of Nobul Technologies Inc.'s business, claiming it was a technology innovator when it primarily operated as a traditional real estate brokerage [7][8]. - There are serious allegations that Mr. McGee and his associates misled investors about Nobul's financial health and used funds for personal enrichment rather than business expansion [12][14]. Group 2: Legal Proceedings - Multiple litigation cases involving Nobul Technologies Inc. and Mr. McGee have been cited, including claims of fraudulent misrepresentation and breach of fiduciary duty [26][30]. - The allegations in these cases include claims that Mr. McGee used Nobul as a façade to deceive investors, leading to significant financial losses for those who invested based on misleading information [13][14]. - The legal actions also highlight governance issues, with former directors expressing concerns about Mr. McGee's control over the company and the lack of transparency in operations [10][11]. Group 3: MediPharm's Position - MediPharm urges shareholders to support its nominees and resolutions by voting with the GREEN proxy, emphasizing the importance of governance and the qualifications of its board members [16][17]. - The company has communicated that shareholders should disregard any outreach from the dissident group and focus on the information provided by MediPharm [18].